Cancer therapy with iRGD as a tumor-penetrating peptide.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cancer therapy with iRGD as a tumor-penetrating peptide.
- Published In:
- Bulletin du cancer, 110(12), 1288-1300 (2023)
- Authors:
- Thirumalai, Anbazhagan, Girigoswami, Koyeli, Pallavi, Pragya, Harini, Karthick, Gowtham, Pemula, Girigoswami, Agnishwar
- Database ID:
- RPEP-07462
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07462APA
Thirumalai, Anbazhagan; Girigoswami, Koyeli; Pallavi, Pragya; Harini, Karthick; Gowtham, Pemula; Girigoswami, Agnishwar. (2023). Cancer therapy with iRGD as a tumor-penetrating peptide.. Bulletin du cancer, 110(12), 1288-1300. https://doi.org/10.1016/j.bulcan.2023.08.009
MLA
Thirumalai, Anbazhagan, et al. "Cancer therapy with iRGD as a tumor-penetrating peptide.." Bulletin du cancer, 2023. https://doi.org/10.1016/j.bulcan.2023.08.009
RethinkPeptides
RethinkPeptides Research Database. "Cancer therapy with iRGD as a tumor-penetrating peptide." RPEP-07462. Retrieved from https://rethinkpeptides.com/research/thirumalai-2023-cancer-therapy-with-irgd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.